ArticleNature nanotechnology2023
Programmable multispecific DNA-origami-based T-cell engagers.
Article in Nature nanotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 98 citations in OpenAlex.
- Single-Cell Proteomics Uncovers Cell-Specific Proteins in Vascular Health and Marfan Syndrome Disease-Brief Report.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- Homogeneous Antibody-DNA Conjugates Using Unmodified Oligonucleotides and Photo-Cross-Linkable Protein G-HUH Endonuclease Fusion Proteins.Bioconjugate chemistry · 2026Article
- Modular nucleic acid-based construct for delivery of immunostimulatory agonists and oncogene-silencing oligonucleotides in tumours.Nature biomedical engineering · 2026Article
- De novo design of DNA origami with a generative diffusion model.Nature communications · 2026Article
- Programmable Lipid Functionalization of Nucleic Acid Nanoparticles Modulates Liver Cell-Type Targeting.ACS applied materials & interfaces · 2026Article
- Engineering a Mechanoresponsive DNA Origami Capsule for Drug Delivery to Narrowed Arteries.Nano letters · 2026Article
- Resolving DNA origami structural integrity and pharmacokinetics in vivo.Nature nanotechnology · 2026Article
- A DNA-based nanodevice senses purinergic signaling and drives an immune switch for resolving inflammation.Nature communications · 2026Article
- Functionalizing Nucleic Acids: Synthesis and Purification Strategies for Bioconjugates as Biomaterials.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- A Facile and Reproducible Method for the Purification of Peptide- and Protein-Functionalized DNA Nanostructures.JACS Au · 2025Article
- Inflammation-specific DNA origami nanodevice for delivery of siRNAs to treat ulcerative colitis.Nature communications · 2025Article
- Nanocarrier imaging at single-cell resolution across entire mouse bodies with deep learning.Nature biotechnology · 2025Article
- Topology Determines DNA Origami Diffusion in Intestinal Mucus.Nano letters · 2025Article
- Real-Time Monitoring of DNA Origami-Cell Interactions via Single Particle Tracking.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Effects of Oligolysine-Polyethylene Glycol Coating on the Biodistribution of Wireframe DNA Origami Nanosheets in Zebrafish Embryos.ACS nano · 2025Article
- Multivalent DNA Origami Enables Single-Molecule Dissection of Integrin αvβ6-Receptor Tyrosine Kinase Crosstalk in Cancer Biology.ACS nano · 2025Article
- Stimuli-Responsive Oligolysine-PEG Coatings for Reductive-Triggered Decomplexation.ACS polymers Au · 2025Article
- Advancements in DNA-Driven Precision Modulation of Cell Surface Receptor for Programmable Cellular Functions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Scaffolding Light-Up Aptamers on DNA Nanostructures for Fluorescence Enhancement.ACS biomaterials science & engineering · 2025Article
- Toward high-density streptavidin arrays on DNA origami nanostructures.RSC advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multispecific antibodies have emerged as versatile therapeutic agents, and therefore, approaches to optimize and streamline their design and assembly are needed. Here we report on the modular and programmable assembly of IgG antibodies, F(ab) and scFv fragments on DNA origami nanocarriers. We screened 105 distinct quadruplet antibody variants in vitro for the ability to activate T cells in the presence of target cells. T-cell engagers were identified, which in vitro showed the specific and efficient T-cell-mediated lysis of five distinct target cell lines. We used these T-cell engagers to target and lyse tumour cells in vivo in a xenograft mouse tumour model. Our approach enables the rapid generation, screening and testing of bi- and multispecific antibodies to facilitate preclinical pharmaceutical development from in vitro discovery to in vivo proof of concept.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.